Amgen, Sandoz Urge Fed. Circ. To Revisit Biosimilar Ruling
Amgen Inc. and Sandoz Inc. on Thursday asked the full Federal Circuit to revisit a fractured panel decision on key elements of the Affordable Care Act's approval pathway for biosimilars, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article